New data reveals that despite the Department of Veterans Affairs’ (VA) assurances, veterans suffering from Inclusion Body Myositis (IBM) face significant challenges in securing disability benefits. A staggering 80% of these veterans are denied the support they need, highlighting a critical gap between VA claims and actual help provided. IBM, a rare muscle-wasting disease, leaves many veterans unable to work, yet their disability applications are frequently rejected. This has sparked concerns among advocacy groups, who argue that the VA must do more to assist those who have served their country. The article delves into individual stories of veterans grappling with this condition and the bureaucratic hurdles they face. It underscores the urgent need for policy changes to ensure that those affected by IBM receive the financial support required to improve their quality of life. As new data continues to surface, it raises questions about the effectiveness of the VA’s current system in addressing the needs of disabled veterans.
11Alive.comNew data shows CLYM116 reduces key IgA nephropathy biomarkers by ~70%, supporting a 12-week dosing regimen
October 24, 2026
New data released by CLIMB Bio and MabWorks reveals that their investigational drug CLYM116 significantly reduces critical biomarkers associated with IgA nephropathy by approximately 70%.